Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(67%)

Phase Distribution

Ph phase_1
2
67%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(2)
Other(1)

Detailed Status

Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

unknown133%
terminated267%

Recent Activity

0 active trials
Showing 3 of 3
unknown

Study of the Practice of Debiri in France

NCT03369041
terminatedphase_1

Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer

NCT01285102
terminatedphase_1

Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver

NCT02110953

Clinical Trials (3)

Showing 3 of 3 trials
NCT03369041

Study of the Practice of Debiri in France

Unknown
NCT01285102Phase 1

Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer

Terminated
NCT02110953Phase 1

Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver

Terminated

All 3 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
3